HLBBF
Price
$5.52
Change
+$0.37 (+7.18%)
Updated
Aug 12 closing price
Capitalization
5.86B
STEK
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Aug 15 closing price
Capitalization
3.66M
Interact to see
Advertisement

HLBBF vs STEK

Header iconHLBBF vs STEK Comparison
Open Charts HLBBF vs STEKBanner chart's image
H. Lundbeck A/S
Price$5.52
Change+$0.37 (+7.18%)
Volume$1.7K
Capitalization5.86B
Stemtech
Price$0.03
Change-$0.00 (-0.00%)
Volume$5.88K
Capitalization3.66M
HLBBF vs STEK Comparison Chart in %
Loading...
HLBBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HLBBF vs. STEK commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HLBBF is a StrongBuy and STEK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (HLBBF: $5.52 vs. STEK: $0.03)
Brand notoriety: HLBBF and STEK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HLBBF: 484% vs. STEK: 4%
Market capitalization -- HLBBF: $5.86B vs. STEK: $3.66M
HLBBF [@Pharmaceuticals: Generic] is valued at $5.86B. STEK’s [@Pharmaceuticals: Generic] market capitalization is $3.66M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HLBBF’s FA Score shows that 1 FA rating(s) are green whileSTEK’s FA Score has 0 green FA rating(s).

  • HLBBF’s FA Score: 1 green, 4 red.
  • STEK’s FA Score: 0 green, 5 red.
According to our system of comparison, HLBBF is a better buy in the long-term than STEK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HLBBF’s TA Score shows that 3 TA indicator(s) are bullish while STEK’s TA Score has 2 bullish TA indicator(s).

  • HLBBF’s TA Score: 3 bullish, 5 bearish.
  • STEK’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, HLBBF is a better buy in the short-term than STEK.

Price Growth

HLBBF (@Pharmaceuticals: Generic) experienced а +7.09% price change this week, while STEK (@Pharmaceuticals: Generic) price change was -6.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HLBBF($5.86B) has a higher market cap than STEK($3.66M). HLBBF YTD gains are higher at: -10.324 vs. STEK (-44.449). HLBBF has higher annual earnings (EBITDA): 4.25B vs. STEK (-3.06M). HLBBF has more cash in the bank: 2.7B vs. STEK (260K). STEK has less debt than HLBBF: STEK (4.07M) vs HLBBF (15.2B). HLBBF has higher revenues than STEK: HLBBF (23B) vs STEK (5.1M).
HLBBFSTEKHLBBF / STEK
Capitalization5.86B3.66M159,934%
EBITDA4.25B-3.06M-139,066%
Gain YTD-10.324-44.44923%
P/E Ratio9.98N/A-
Revenue23B5.1M450,804%
Total Cash2.7B260K1,037,308%
Total Debt15.2B4.07M373,924%
FUNDAMENTALS RATINGS
STEK: Fundamental Ratings
STEK
OUTLOOK RATING
1..100
82
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
PROFIT vs RISK RATING
1..100
99
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
84
P/E GROWTH RATING
1..100
93
SEASONALITY SCORE
1..100
30

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
HLBBFSTEK
RSI
ODDS (%)
Bullish Trend 2 days ago
45%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
52%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
32%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
38%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
46%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
36%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
HLBBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VMSGX22.67N/A
N/A
VALIC Company I Mid Cap Strategic Gr
UGMVX11.98N/A
N/A
Victory Global Managed Volatility
RYZCX134.46N/A
N/A
Rydex Precious Metals C
TRWFX25.19N/A
N/A
Transamerica International Equity R4
CGFEX81.95-0.06
-0.07%
American Funds Growth Fund of Amer 529E

HLBBF and

Correlation & Price change

A.I.dvisor tells us that HLBBF and HYEX have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HLBBF and HYEX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLBBF
1D Price
Change %
HLBBF100%
N/A
HYEX - HLBBF
21%
Poorly correlated
N/A
HLUBF - HLBBF
18%
Poorly correlated
N/A
HLN - HLBBF
10%
Poorly correlated
+0.09%
HLNCF - HLBBF
8%
Poorly correlated
+2.77%
STEK - HLBBF
2%
Poorly correlated
+0.55%
More

STEK and

Correlation & Price change

A.I.dvisor tells us that STEK and CNADF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that STEK and CNADF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STEK
1D Price
Change %
STEK100%
+0.55%
CNADF - STEK
25%
Poorly correlated
N/A
BFRI - STEK
12%
Poorly correlated
-3.73%
HLNCF - STEK
11%
Poorly correlated
+2.77%
PLSH - STEK
8%
Poorly correlated
N/A
EAPIF - STEK
6%
Poorly correlated
N/A
More